Class information for: |
Basic class information |
| Class id | #P | Avg. number of references |
Database coverage of references |
|---|---|---|---|
| 35514 | 96 | 41.9 | 90% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
| Cluster id | Level | Cluster label | #P |
|---|---|---|---|
| 0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
| 317 | 3 | HER2//TRASTUZUMAB//CHRONIC MYELOID LEUKEMIA | 39408 |
| 1452 | 2 | CHRONIC MYELOID LEUKEMIA//IMATINIB//NILOTINIB | 7818 |
| 35514 | 1 | AG 1295//BONE CANC SMYELOMA//CAREGGI UNIV HOSP INTERNAL MEDAOU CAREGGI | 96 |
Terms with highest relevance score |
| rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
|---|---|---|---|---|---|---|
| 1 | AG 1295 | authKW | 318080 | 1% | 100% | 1 |
| 2 | BONE CANC SMYELOMA | address | 318080 | 1% | 100% | 1 |
| 3 | CAREGGI UNIV HOSP INTERNAL MEDAOU CAREGGI | address | 318080 | 1% | 100% | 1 |
| 4 | CLIN PHARM BIOPHARRNACY | address | 318080 | 1% | 100% | 1 |
| 5 | CRICMCNRSUMR7225INSERM | address | 318080 | 1% | 100% | 1 |
| 6 | ENDOC1 BETA H1 | authKW | 318080 | 1% | 100% | 1 |
| 7 | FIBROSISA | authKW | 318080 | 1% | 100% | 1 |
| 8 | HAEMATOL MED VET SCI CANC BIOL | address | 318080 | 1% | 100% | 1 |
| 9 | HAEMATOLHAUSON | address | 318080 | 1% | 100% | 1 |
| 10 | HANSON LEVEL 2 | address | 318080 | 1% | 100% | 1 |
Web of Science journal categories |
| Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
|---|---|---|---|---|---|
| 1 | Hematology | 575 | 24% | 0% | 23 |
| 2 | Endocrinology & Metabolism | 574 | 30% | 0% | 29 |
| 3 | Oncology | 242 | 27% | 0% | 26 |
| 4 | Cell & Tissue Engineering | 103 | 3% | 0% | 3 |
| 5 | Medicine, Research & Experimental | 76 | 11% | 0% | 11 |
| 6 | Cell Biology | 42 | 13% | 0% | 12 |
| 7 | CYTOLOGY & HISTOLOGY | 40 | 1% | 0% | 1 |
| 8 | Multidisciplinary Sciences | 28 | 3% | 0% | 3 |
| 9 | Pharmacology & Pharmacy | 18 | 10% | 0% | 10 |
| 10 | Medicine, General & Internal | 9 | 6% | 0% | 6 |
Address terms |
| Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
|---|---|---|---|---|---|
| 1 | BONE CANC SMYELOMA | 318080 | 1% | 100% | 1 |
| 2 | CAREGGI UNIV HOSP INTERNAL MEDAOU CAREGGI | 318080 | 1% | 100% | 1 |
| 3 | CLIN PHARM BIOPHARRNACY | 318080 | 1% | 100% | 1 |
| 4 | CRICMCNRSUMR7225INSERM | 318080 | 1% | 100% | 1 |
| 5 | HAEMATOL MED VET SCI CANC BIOL | 318080 | 1% | 100% | 1 |
| 6 | HAEMATOLHAUSON | 318080 | 1% | 100% | 1 |
| 7 | HANSON LEVEL 2 | 318080 | 1% | 100% | 1 |
| 8 | HANSON MYELOMA CANC BIOL | 318080 | 1% | 100% | 1 |
| 9 | HAUSON | 318080 | 1% | 100% | 1 |
| 10 | INSERM U1185 | 318080 | 1% | 100% | 1 |
Journals |
| Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
|---|---|---|---|---|---|
| 1 | JOURNAL OF BONE AND MINERAL METABOLISM | 1996 | 3% | 0% | 3 |
| 2 | LEUKEMIA RESEARCH | 1891 | 6% | 0% | 6 |
| 3 | PHARMACOLOGICAL REPORTS | 1594 | 3% | 0% | 3 |
| 4 | JOURNAL OF ONCOLOGY PHARMACY PRACTICE | 1542 | 1% | 0% | 1 |
| 5 | TISSUE ENGINEERING PART B-REVIEWS | 877 | 1% | 0% | 1 |
| 6 | ENDOCRINE-RELATED CANCER | 767 | 2% | 0% | 2 |
| 7 | HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM | 723 | 1% | 0% | 1 |
| 8 | BIOSCIENCE TRENDS | 686 | 1% | 0% | 1 |
| 9 | EXPERT OPINION ON INVESTIGATIONAL DRUGS | 590 | 2% | 0% | 2 |
| 10 | TISSUE ENGINEERING PART A | 539 | 2% | 0% | 2 |
Author Key Words |
| Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | AG 1295 | 318080 | 1% | 100% | 1 | Search AG+1295 | Search AG+1295 |
| 2 | ENDOC1 BETA H1 | 318080 | 1% | 100% | 1 | Search ENDOC1+BETA+H1 | Search ENDOC1+BETA+H1 |
| 3 | FIBROSISA | 318080 | 1% | 100% | 1 | Search FIBROSISA | Search FIBROSISA |
| 4 | HYPOLIPEMIANT AND ANTIDIABETIC EFFECT | 318080 | 1% | 100% | 1 | Search HYPOLIPEMIANT+AND+ANTIDIABETIC+EFFECT | Search HYPOLIPEMIANT+AND+ANTIDIABETIC+EFFECT |
| 5 | IMANITIB MESYLATE | 318080 | 1% | 100% | 1 | Search IMANITIB+MESYLATE | Search IMANITIB+MESYLATE |
| 6 | INSUFFICIENT FRACTURE | 318080 | 1% | 100% | 1 | Search INSUFFICIENT+FRACTURE | Search INSUFFICIENT+FRACTURE |
| 7 | OSI420 | 318080 | 1% | 100% | 1 | Search OSI420 | Search OSI420 |
| 8 | PDGF BB PDGF BETA RECEPTOR | 318080 | 1% | 100% | 1 | Search PDGF+BB+PDGF+BETA+RECEPTOR | Search PDGF+BB+PDGF+BETA+RECEPTOR |
| 9 | PIP3 SIGNALLING | 318080 | 1% | 100% | 1 | Search PIP3+SIGNALLING | Search PIP3+SIGNALLING |
| 10 | BONE MARROW MILIEU | 159039 | 1% | 50% | 1 | Search BONE+MARROW+MILIEU | Search BONE+MARROW+MILIEU |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
| Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
|---|---|---|---|---|
| 1 | O'SULLIVAN, S , TAY, ML , LIN, JM , BAVA, U , CALLON, K , CORNISH, J , NAOT, D , GREY, A , (2016) TYROSINE KINASE INHIBITORS REGULATE OPG THROUGH INHIBITION OF PDGFR BETA.PLOS ONE. VOL. 11. ISSUE 10. P. - | 18 | 55% | 0 |
| 2 | FOUNTAS, A , DIAMANTOPOULOS, LN , TSATSOULIS, A , (2015) TYROSINE KINASE INHIBITORS AND DIABETES: A NOVEL TREATMENT PARADIGM?.TRENDS IN ENDOCRINOLOGY AND METABOLISM. VOL. 26. ISSUE 11. P. 643 -656 | 23 | 37% | 6 |
| 3 | MALEK, R , DAVIS, SN , (2016) TYROSINE KINASE INHIBITORS UNDER INVESTIGATION FOR THE TREATMENT OF TYPE II DIABETES.EXPERT OPINION ON INVESTIGATIONAL DRUGS. VOL. 25. ISSUE 3. P. 287 -296 | 16 | 52% | 1 |
| 4 | BRECCIA, M , MOLICA, M , ALIMENA, G , (2014) HOW TYROSINE KINASE INHIBITORS IMPAIR METABOLISM AND ENDOCRINE SYSTEM FUNCTION: A SYSTEMATIC UPDATED REVIEW.LEUKEMIA RESEARCH. VOL. 38. ISSUE 12. P. 1392 -1398 | 19 | 39% | 8 |
| 5 | HOEHN, D , MEDEIROS, LJ , KANTARJIAN, HM , CORTES, JE , WANG, XM , BUESO-RAMOS, CE , (2012) DIGITAL IMAGE ANALYSIS AS A TOOL TO ASSESS THE EFFECTS OF IMATINIB ON TRABECULAR BONE IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA.HUMAN PATHOLOGY. VOL. 43. ISSUE 12. P. 2354-2359 | 11 | 69% | 1 |
| 6 | ALEMAN, JO , FAROOKI, A , GIROTRA, M , (2014) EFFECTS OF TYROSINE KINASE INHIBITION ON BONE METABOLISM: UNTARGETED CONSEQUENCES OF TARGETED THERAPIES.ENDOCRINE-RELATED CANCER. VOL. 21. ISSUE 3. P. R247 -R259 | 20 | 32% | 14 |
| 7 | JONSSON, S , HJORTH-HANSEN, H , OLSSON, B , WADENVIK, H , SUNDAN, A , STANDAL, T , (2012) IMATINIB INHIBITS PROLIFERATION OF HUMAN MESENCHYMAL STEM CELLS AND PROMOTES EARLY BUT NOT LATE OSTEOBLAST DIFFERENTIATION IN VITRO.JOURNAL OF BONE AND MINERAL METABOLISM. VOL. 30. ISSUE 1. P. 119-123 | 10 | 63% | 18 |
| 8 | BERMAN, E , GIROTRA, M , CHENG, C , CHANEL, S , MAKI, R , SHELAT, M , STRAUSS, HW , FLEISHER, M , HELLER, G , FAROOKI, A , (2013) EFFECT OF LONG TERM IMATINIB ON BONE IN ADULTS WITH CHRONIC MYELOGENOUS LEUKEMIA AND GASTROINTESTINAL STROMAL TUMORS.LEUKEMIA RESEARCH. VOL. 37. ISSUE 7. P. 790-794 | 11 | 55% | 11 |
| 9 | LEE, Y , JUNG, HS , CHOI, HJ , KIM, MJ , KIM, TM , PARK, KS , KIM, SY , (2011) LIFE-THREATENING HYPOGLYCEMIA INDUCED BY A TYROSINE KINASE INHIBITOR IN A PATIENT WITH NEUROENDOCRINE TUMOR: A CASE REPORT.DIABETES RESEARCH AND CLINICAL PRACTICE. VOL. 93. ISSUE 2. P. E68 -E70 | 7 | 88% | 7 |
| 10 | HOEHN, D , CORTES, JE , MEDEIROS, LJ , JABBOUR, EJ , HIDALGO, JE , KANAGAL-SHAMANNA, R , BUESO-RAMOS, CE , (2016) MULTIPARAMETER ANALYSIS OF OFF-TARGET EFFECTS OF DASATINIB ON BONE HOMEOSTASIS IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOGENOUS LEUKEMIA.CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. VOL. 16. ISSUE . P. S86 -S92 | 14 | 40% | 0 |
Classes with closest relation at Level 1 |